Pravastatin and simvastatin improves acetylsalicylic acid-mediated in vitro blood platelet inhibition

European Journal of Clinical Investigation

Volumn 42, Issue 8, 2012, Pages 864-872

  Luzak, Boguslawa ^a   Rywaniak, Joanna ^a   Stanczyk, Lidia ^a   Watala, Cezary ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Acetylsalicylic acid; Cholesterol; Platelet reactivity; Pravastatin; Simvastatin; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ATORVASTATIN; CD36 ANTIGEN; COLLAGEN; DUAL SPECIFICITY PHOSPHATASE 2; PADGEM PROTEIN; PRAVASTATIN; SIMVASTATIN; THROMBOXANE;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; VOLUNTEER;

ADULT; ASPIRIN; BLOOD PLATELETS; CHOLESTEROL; DRUG INTERACTIONS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PRAVASTATIN; PYRROLES; SIMVASTATIN; YOUNG ADULT;

EID: 84864012186     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2012.02661.x     Document Type: Article

References (25)

1. Awtry EH, Loscalzo J. Aspirin. Circulation 2000;101:1206-18.
2. Szczeklik A, Musial J, Undas A, Sanak M. Aspirin resistance. J Thromb Haemost 2005;3:1655-62.
3. Comparato C, Altana C, Bellosta S, Baetta R, Paoletti R, Corsini A. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction? Nutr Metab Cardiovasc Dis 2001;11:328-43.
4. Puccetti L, Pasqui AL, Auteri A, Bruni F. Mechanisms for antiplatelet action of statins. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:121-6.
5. Chapman MJ. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention. Pharmacol Ther 2007;113:184-96.
6. Luzak B, Boncler M, Rywaniak J, Wilk R, Stanczyk L, Czyz M et al. The effect of a platelet cholesterol modulation on the acetylsalicylic acid-mediated blood platelet inhibition in hypercholesterolemic patients. Eur J Pharmacol 2011;658:91-7.
7. Boncler M, Gresner P, Nocun M, Rywaniak J, Dolnik M, Rysz J et al. Elevated cholesterol reduces acetylsalicylic acid-mediated platelet acetylation. Biochim Biophys Acta 2007;1770:1651-9.
8. Hamada M, Sugimoto M, Matsui H, Mizuno T, Shida Y, Doi M et al. Antithrombotic properties of pravastatin reducing intra-thrombus fibrin deposition under high shear blood flow conditions. Thromb Haemost 2011;105:313-20.
9. Marwali MR, Hu CP, Mohandas B, Dandapat A, Deonikar P, Chen J et al. Modulation of ADP-induced platelet activation by aspirin and pravastatin: role of lectin-like oxidized low-density lipoprotein receptor-1, nitric oxide, oxidative stress, and inside-out integrin signaling. J Pharmacol Exp Ther 2007;322:1324-32.
10. Santos MT, Fuset MP, Ruano M, Moscardo A, Valles J. Effect of atorvastatin on platelet thromboxane A(2) synthesis in aspirin-treated patients with acute myocardial infarction. Am J Cardiol 2009;104:1618-23.
11. Wieclawska B, Rozalski M, Trojanowski Z, Watala C. Modulators of intraplatelet calcium concentration affect the binding of thrombospondin to blood platelets in healthy donors and patients with type 2 diabetes mellitus. Eur J Haematol 2001;66:396-403.
12. Watala C, Pluta J, Golanski J, Rozalski M, Czyz M, Trojanowski Z et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med 2005;83:148-58.
13. Verstraeten SV, Oteiza PI. Sc3+, Ga3+, In3+, Y3+, and Be2+ promote changes in membrane physical properties and facilitate Fe2(+)-initiated lipid peroxidation. Arch Biochem Biophys 1995;322:284-90.
14. Undas A, Siudak Z, Topor-Madry R, Lesniak M, Tracz W. Simvastatin administration reduces thromboxane production in subjects taking aspirin: links between aspirin resistance and thrombin generation. Int J Cardiol 2012;154:59-64.
15. Mason R, Walter M, Day C, Jacob R. Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism. J Biol Chem 2006;281:9337-45.
16. Silverstein RL. Type 2 scavenger receptor CD36 in platelet activation: the role of hyperlipemia and oxidative stress. Clin Lipidol 2009;4:767.
17. Bruni F, Pasqui AL, Pastorelli M, Bova G, Cercignani M, Palazzuoli A et al. Different effect of statins on platelet oxidized-LDL receptor (CD36 and LOX-1) expression in hypercholesterolemic subjects. Clin Appl Thromb Hemost 2005;11:417-28.
18. Puccetti L, Sawamura T, Pasqui AL, Pastorelli M, Auteri A, Bruni F. Atorvastatin reduces platelet-oxidized-LDL receptor expression in hypercholesterolaemic patients. Eur J Clin Invest 2005;35:47-51.
19. Fuhrman B, Koren L, Volkova N, Keidar S, Hayek T, Aviram M. Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis 2002;164:179-85.
20. Han J, Zhou X, Yokoyama T, Hajjar DP, Gotto AM Jr, Nicholson AC. Pitavastatin downregulates expression of the macrophage type B scavenger receptor, CD36. Circulation 2004;109:790-6.
21. Mason RP, Walter MF, Day CA, Jacob RF. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol 2005;96:11F-23F.
22. Niessen J, Jedlitschky G, Grube M, Bien S, Schwertz H, Ohtsuki S et al. Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. Drug Metab Dispos 2009;37:1129-37.
23. Osamah H, Mira R, Sorina S, Shlomo K, Michael A. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Br J Clin Pharmacol 1997;44:77-83.
24. Puccetti L, Bruni F, Di Renzo M, Bova G, Cercignani M, Iadanza A et al. Hypercoagulable state in hypercholesterolemic subjects assessed by platelet-dependent thrombin generation. In vitro effect of cerivastatin. Eur Rev Med Pharmacol Sci 1999;3:197-204.
25. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975;56:624-32.